Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE versus TRIESENCE.
Betamethasone vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression, resulting in anti-inflammatory and immunosuppressive effects. It also suppresses the hypothalamic-pituitary-adrenal axis.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
0.6 to 9 mg/day orally in divided doses; intramuscularly, 0.5 to 9 mg/day; intravenously, up to 12 mg/day; topical (as valerate or dipropionate) applied thinly to affected area once to twice daily.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Clinical Note
moderateBetamethasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin."
Clinical Note
moderateBetamethasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin."
Clinical Note
moderateBetamethasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 6.4 hours (range 4.3-9.4 hours). Clinically, adrenal suppression lasts 2.7-3.5 days after single dose.
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Primarily renal: ~60% as metabolites, <5% unchanged. Biliary/fecal: ~15-20%.
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category A/B
Category C
Corticosteroid
Corticosteroid
Betamethasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Trovafloxacin."